NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (OTCBB: ADXS), a biotechnology company developing novel Listeria-based therapeutic cancer vaccines, has been profiled in both Genetic Engineering News and R&D Directions, two leading biotech publications. The publications highlighted Advaxis’ Listeria platform technology and their advancement in building a family of cancer vaccines based on exploiting the powerful immune response and antigen-carrying capabilities of the bacterium Listeria monocytogenes.
